Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

Also called NCT03753269

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03753269
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03753269. Randomized; double masking; primary purpose treatment. Start 2019-07-01 (anticipated); primary completion 2022-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
Condition
ST Segment Elevation Myocardial Infarction
Intervention (Drug)
Fasudil Hydrochloride
Intervention (Drug)
Placebo saline
Lead sponsor
RenJi Hospital (class: other)

Record details

Record id
cardio:ct-nct03753269
Content hash
3dc597936374fbd9e2a07647134f9847170a4cec5892266d56bad7a35869db27